Skip to main content

Advertisement

SpringerLink
Log in

Challenges in randomized controlled trials and emerging multiple sclerosis therapeutics

  • Review
  • Published:
Neuroscience Bulletin Aims and scope Submit manuscript

Abstract

The remarkable global development of disease-modifying therapies (DMTs) specific for multiple sclerosis (MS) has significantly reduced the frequency of relapse, slowed the progression of disability, and improved the quality of life in patients with MS. With increasing numbers of approved DMTs, neurologists in North America and Europe are able to present multiple treatment options to their patients to achieve a better therapeutic outcome, and in many cases, no evidence of disease activity. MS patients have improved accessibility to various DMTs at no or minimal out-of-pocket cost. The ethical guidelines defined by the Edinburgh revision of the Declaration of Helsinki strongly discourage the use of placebo control groups in modern MS clinical trials. The use of an active comparator control group increases the number of participants in each group that is essential to achieve statistical significance, thus further increasing the difficulty of completing randomized controlled trials (RCTs) for the development of new MS therapies. There is evidence of a high prevalence of MS and a large number of patients in Asia. The belief of the existence of Asian types of MS that are distinct from Western types, and regulatory policies are among the reasons why DMTs are limited in most Asian countries. Lack of access to approved DMTs provides a good opportunity for clinical trials that are designed for the development of new MS therapies. Recently, data from RCTs have demonstrated excellent recruitment of participants and the completion of multi-nation and single-nation MS trials within this region. Recent studies using the McDonald MS diagnostic criteria carefully excluded patients with neuromyelitis optica (NMO) and NMO spectrum disorder, and demonstrated that patients with MS in Asia have clinical characteristics and treatment responses similar to those in Western countries.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Birnbaum G. Current and future treatments for relapsingremitting multiple sclerosis. Curr Opin Drug Discov Devel 2010, 13: 214–225.

    CAS  PubMed  Google Scholar 

  2. Cross AH, Naismith RT. Established and novel diseasemodifying treatments in multiple sclerosis. J Intern Med 2014, 275: 350–363.

    Article  CAS  PubMed  Google Scholar 

  3. Mitsumoto J, Dorsey ER, Beck CA, Kieburtz K, Griggs RC. Pivotal studies of orphan drugs approved for neurological diseases. Ann Neurol 2009, 66: 184–190.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  4. Fox RJ, Miller DH, Phillips JT, Hutchinson M, Havrdova E, Kita M, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med 2012, 367: 1087–1097.

    Article  CAS  PubMed  Google Scholar 

  5. Phillips JT, Fox RJ. BG-12 in multiple sclerosis. Semin Neurol 2013, 33: 56–65.

    Article  PubMed  Google Scholar 

  6. Cohen JA, Chun J. Mechanisms of fingolimod’s efficacy and adverse effects in multiple sclerosis. Ann Neurol 2011, 69: 759–777.

    Article  CAS  PubMed  Google Scholar 

  7. Hartung HP. Interferon beta-1a for multiple sclerosis: old drug, new clothes. Lancet Neurol 2014, 13: 638–639.

    Article  CAS  PubMed  Google Scholar 

  8. Cohen JA, Barkhof F, Comi G, Hartung HP, Khatri BO, Montalban X, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010, 362: 402–415.

    Article  CAS  PubMed  Google Scholar 

  9. Kappos L, Radue EW, O’ Connor P, Polman C, Hohlfeld R, Calabresi P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010, 362: 387–401.

    Article  CAS  PubMed  Google Scholar 

  10. Bar-Or A, Pachner A, Menguy-Vacheron F, Kaplan J, Wiendl H. Teriflunomide and its mechanism of action in multiple sclerosis. Drugs 2014, 74: 659–674.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  11. Confavreux C, O’Connor P, Comi G, Freedman MS, Miller AE, Olsson TP, et al. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, doubleblind, placebo-controlled, phase 3 trial. Lancet Neurol 2014, 13: 247–256.

    Article  CAS  PubMed  Google Scholar 

  12. Miller AE, Wolinsky JS, Kappos L, Comi G, Freedman MS, Olsson TP, et al. Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol 2014, 13: 977–986.

    Article  CAS  PubMed  Google Scholar 

  13. O’Connor P, Wolinsky JS, Confavreux C, Comi G, Kappos L, Olsson TP, et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med 2011, 365: 1293–1303.

    Article  PubMed  Google Scholar 

  14. Gold R, Kappos L, Arnold DL, Bar-Or A, Giovannoni G, Selmaj K, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med 2012, 367: 1098–1107.

    Article  CAS  PubMed  Google Scholar 

  15. Polman CH, O’ Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006, 354: 899–910.

    Article  CAS  PubMed  Google Scholar 

  16. Rudick RA, Stuart WH, Calabresi PA, Confavreux C, Galetta SL, Radue EW, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 2006, 354: 911–923.

    Article  CAS  PubMed  Google Scholar 

  17. Coles AJ, Twyman CL, Arnold DL, Cohen JA, Confavreux C, Fox EJ, et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet 2012, 380: 1829–1839.

    Article  CAS  PubMed  Google Scholar 

  18. Menge T, Stuve O, Kieseier BC, Hartung HP. Alemtuzumab: the advantages and challenges of a novel therapy in MS. Neurology 2014, 83: 87–97.

    Article  CAS  PubMed  Google Scholar 

  19. Cohen JA, Coles AJ, Arnold DL, Confavreux C, Fox EJ, Hartung HP, et al. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet 2012, 380: 1819–1828.

    Article  CAS  PubMed  Google Scholar 

  20. Saunders J, Wainwright P. Risk, Helsinki 2000 and the use of placebo in medical research. Clin Med 2003, 3: 435–439.

    Article  PubMed  Google Scholar 

  21. Salako SE. The declaration of Helsinki 2000: ethical principles and the dignity of difference. Med Law 2006, 25: 341–354.

    CAS  PubMed  Google Scholar 

  22. Emanuel EJ, Miller FG. The ethics of placebo-controlled trials—a middle ground. N Engl J Med 2001, 345: 915–919.

    Article  CAS  PubMed  Google Scholar 

  23. Polman CH, Reingold SC, Barkhof F, Calabresi PA, Clanet M, Cohen JA, et al. Ethics of placebo-controlled clinical trials in multiple sclerosis: a reassessment. Neurology 2008, 70: 1134–1140.

    Article  CAS  PubMed  Google Scholar 

  24. Calabresi PA, Kieseier BC, Arnold DL, Balcer LJ, Boyko A, Pelletier J, et al. Pegylated interferon beta-1a for relapsingremitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study. Lancet Neurol 2014, 13: 657–665.

    Article  CAS  PubMed  Google Scholar 

  25. Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ, Weinshenker BG. The spectrum of neuromyelitis optica. Lancet Neurol 2007, 6: 805–815.

    Article  CAS  PubMed  Google Scholar 

  26. Wingerchuk DM, Weinshenker BG. Neuromyelitis optica (Devic’s syndrome). Handb Clin Neurol 2014, 122: 581–599.

    Article  PubMed  Google Scholar 

  27. Cheng Q, Miao L, Zhang J, Guan YT, Liu ZG, Wang X, et al. Clinical features of patients with multiple sclerosis from a survey in Shanghai, China. Mult Scler 2008, 14: 671–678.

    Article  CAS  PubMed  Google Scholar 

  28. Cheng Q, Miao L, Zhang J, Ding SJ, Liu ZG, Wang X, et al. A population-based survey of multiple sclerosis in Shanghai, China. Neurology 2007, 68: 1495–1500.

    Article  CAS  PubMed  Google Scholar 

  29. Houzen H, Niino M, Kikuchi S, Fukazawa T, Nogoshi S, Matsumoto H, et al. The prevalence and clinical characteristics of MS in northern Japan. J Neurol Sci 2003, 211: 49–53.

    Article  PubMed  Google Scholar 

  30. Houzen H, Niino M, Hirotani M, Fukazawa T, Kikuchi S, Tanaka K, et al. Increased prevalence, incidence, and female predominance of multiple sclerosis in northern Japan. J Neurol Sci 2012, 323: 117–122.

    Article  PubMed  Google Scholar 

  31. Wasay M, Khatri IA, Khealani B, Sheerani M. MS in Asian countries. Int MS J 2006, 13: 58–65.

    CAS  PubMed  Google Scholar 

  32. Cree BA, Khan O, Bourdette D, Goodin DS, Cohen JA, Marrie RA, et al. Clinical characteristics of African Americans vs Caucasian Americans with multiple sclerosis. Neurology 2004, 63: 2039–2045.

    Article  CAS  PubMed  Google Scholar 

  33. Bertolotto A, Gilli F. Interferon-beta responders and nonresponders. A biological approach. Neurol Sci 2008, 29 Suppl 2: S216–217.

    Google Scholar 

  34. Sellner J, Boggild M, Clanet M, Hintzen RQ, Illes Z, Montalban X, et al. EFNS guidelines on diagnosis and management of neuromyelitis optica. Eur J Neurol 2010, 17: 1019–1032.

    Article  CAS  PubMed  Google Scholar 

  35. Kim SH, Huh SY, Kim W, Park MS, Ahn SW, Cho JY, et al. Clinical characteristics and outcome of multiple sclerosis in Korea: does multiple sclerosis in Korea really differ from that in the Caucasian populations? Mult Scler 2013, 19: 1493–1498.

    Article  PubMed  Google Scholar 

  36. Saida T, Kikuchi S, Itoyama Y, Hao Q, Kurosawa T, Nagato K, et al. A randomized, controlled trial of fingolimod (FTY720) in Japanese patients with multiple sclerosis. Mult Scler 2012, 18: 1269–1277.

    Article  CAS  PubMed  Google Scholar 

  37. Kira J, Itoyama Y, Kikuchi S, Hao Q, Kurosawa T, Nagato K, et al. Fingolimod (FTY720) therapy in Japanese patients with relapsing multiple sclerosis over 12 months: results of a phase 2 observational extension. BMC Neurol 2014, 14: 21.

    Article  PubMed Central  PubMed  Google Scholar 

  38. Shi FD, Jia JP. Neurology and neurologic practice in China. Neurology 2011, 77: 1986–1992.

    Article  PubMed Central  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Multiple Sclerosis Center, Neurology and Neuroscience Associates, Inc., Akron, OH, USA

    DeRen Huang

Authors
  1. DeRen Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to DeRen Huang.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Huang, D. Challenges in randomized controlled trials and emerging multiple sclerosis therapeutics. Neurosci. Bull. 31, 745–754 (2015). https://doi.org/10.1007/s12264-015-1560-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12264-015-1560-6

Keywords

Search

Navigation